Get the Stockscreener App
11.82
2.64%
-0.32
After Hours:
11.85
0.03
+0.25%
Ocular Therapeutix Inc stock is traded at $11.82, with a volume of 2.50M.
It is down -2.64% in the last 24 hours and up +5.07% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$12.14
Open:
$12.08
24h Volume:
2.50M
Relative Volume:
0.78
Market Cap:
$2.52B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-8.7556
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
-5.89%
1M Performance:
+5.07%
6M Performance:
+24.95%
1Y Performance:
+35.24%
1-Day Range:
$11.60
$12.19
1-Week Range:
$11.60
$12.66
52-Week Range:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.82 | 2.59B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales - Yahoo Finance
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD - Finviz
Fat Pitch FinancialsOcular Therapeutix, Inc.Common Stock (Nasdaq:OCUL) Stock Quote - FinancialContent
Ocular Therapeutix announces first patient randomized in HELIOS-3 program - MSN
Ocular Therapeutix Earnings Notes - Trefis
Voya Investment Management LLC Trims Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Assenagon Asset Management S.A. Sells 148,100 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Trading Systems Reacting to (OCUL) Volatility - Stock Traders Daily
Revenue per share of Ocular Therapeutix Inc – BER:0OT - TradingView — Track All Markets
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt? - 富途牛牛
Aug Action: Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Sentiment Report & High Yield Stock Recommendations - Улправда
What is the fair value of Ocular Therapeutix Inc. stock nowTrade Volume Report & Long Hold Capital Preservation Plans - ulpravda.ru
Can Ocular Therapeutix Inc. stock hit analyst price targetsMarket Performance Recap & Capital Protection Trade Alerts - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock worth buying before Fed action2025 Top Gainers & Verified Short-Term Plans - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Volume Summary: What is the fair value of Ocular Therapeutix Inc. stock now - ulpravda.ru
Can Ocular Therapeutix Inc. (0OT) stock retain market dominanceEarnings Recap Summary & Weekly Stock Performance Updates - DonanımHaber
How Ocular Therapeutix Inc. stock reacts to job market dataWeekly Trading Summary & Real-Time Buy Signal Alerts - DonanımHaber
What makes Ocular Therapeutix Inc. stock attractive to growth funds2025 Market WrapUp & Real-Time Market Sentiment Reports - DonanımHaber
Why analysts raise outlook for Ocular Therapeutix Inc. (0OT) stock2025 Pullback Review & Community Trade Idea Sharing Platform - Улправда
Is Ocular Therapeutix Inc. stock in correction or buying zoneQuarterly Profit Report & Smart Swing Trading Alerts - Улправда
How Ocular Therapeutix Inc. stock benefits from global expansion2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Will Ocular Therapeutix Inc. stock reach all time highs in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - ulpravda.ru
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 4.3%What's Next? - MarketBeat
Ocular Therapeutix enters quiet period ahead of SOL-1 milestone - MSN
Assessing Ocular Therapeutix (OCUL) Valuation After Accelerated FDA Filing Plan for AXPAXLI in Wet AMD - Sahm
Ocular Therapeutix stock could see 45% upside if trial succeeds, TD Cowen says - Investing.com Canada
RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating - marketscreener.com
Ocular Therapeutix prepares NDA submission for wet AMD drug - MSN
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Avoiding Lag: Real-Time Signals in (OCUL) Movement - news.stocktradersdaily.com
Ocular Therapeutix Inc. (OCUL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission - Insider Monkey
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Insider Monkey
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Is Ocular Therapeutix Inc a good long term investmentAnalyst Downgrades & Big Gains Low Investment - earlytimes.in
(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025 - ts2.tech
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Chardan Capital Maintains Buy Rating on OCUL with $21 Price Targ - GuruFocus
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD - Eyes On Eyecare
Ocular Therapeutix: Not So Fast On The Single-Trial Bet (Rating Downgrade) (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix stock price target raised to $30 by RBC on wAMD trial outlook - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD By Investing.com - Investing.com Canada
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
OCUL Stock Surge: Analysts Weigh In - StocksToTrade
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission By Investing.com - Investing.com Australia
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):